Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q1 2026
Cumberland Pharmaceuticals (CPIX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
Cumberland Pharmaceuticals (CPIX) reported revenue of $9.1M for the first quarter 2026 (Q1 2026), -22% from a year earlier and -33% from the quarter before. Operating margin was -34.3%, net loss $3.3M (36.0% of revenue).
Cumberland Pharmaceuticals, Q1 2026: revenue $9.1M (-22% year over year), operating margin -34.3%, net loss $3.3M, operating cash flow $387K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.1M | -33% | -22% |
| Operating profit | −$3.1M | — | -342% |
| Net earnings | −$3.3M | — | -361% |
| Operating cash flow | $387K | 128× | -90% |
What changed
Revenue was $9.1M in Q1 2026, down 22% year over year and down 33% from the previous quarter. Sancuso was the largest line at 32% of revenue. Other revenue lost $3.0M year over year (down 95%), 115% of the total change.
Operating costs exceeded revenue by $3.1M, an operating margin of -34.3%. Total costs grew 18% against a revenue fall of 22%. The fastest-growing cost line was Cost of revenue (+36%). The quarter ended with a net loss of $3.3M, wider than the previous quarter's $1.4M loss.
Operating cash flow was $387K (down 90% year over year). Non-cash charges added back $1.3M of depreciation and amortization and $107K of share-based compensation. Working capital and other items added $2.3M.
Questions
What was Cumberland Pharmaceuticals' revenue in the first quarter 2026?
Cumberland Pharmaceuticals (CPIX) reported revenue of $9.1M for the first quarter 2026 (Q1 2026), -22% from a year earlier and -33% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $3.1M (-34.3% of revenue) and net loss $3.3M.